Asian Value Stocks Estimated At 15.2% To 40.3% Below Intrinsic Worth

Simply Wall St

Amidst a backdrop of global economic uncertainty and shifting monetary policies, Asian markets have shown resilience, with investor interest particularly piqued by the potential for undervalued opportunities. In this context, identifying stocks priced below their intrinsic worth can be a strategic move for investors looking to capitalize on market inefficiencies and long-term growth potential.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

NameCurrent PriceFair Value (Est)Discount (Est)
Xi'an NovaStar Tech (SZSE:301589)CN¥155.56CN¥303.6448.8%
Nippon Thompson (TSE:6480)¥722.00¥1394.1948.2%
Ningxia Building Materials GroupLtd (SHSE:600449)CN¥13.08CN¥26.0249.7%
Morimatsu International Holdings (SEHK:2155)HK$8.33HK$16.0448.1%
MNC SolutionLtd (KOSE:A484870)₩124900.00₩243739.8948.8%
LianChuang Electronic TechnologyLtd (SZSE:002036)CN¥10.59CN¥20.4348.2%
H.U. Group Holdings (TSE:4544)¥3402.00¥6592.5948.4%
COVER (TSE:5253)¥1580.00¥3098.0849%
China Beststudy Education Group (SEHK:3978)HK$4.68HK$9.3049.7%
Beijing Roborock Technology (SHSE:688169)CN¥154.07CN¥301.1548.8%

Click here to see the full list of 275 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

We'll examine a selection from our screener results.

Damai Entertainment Holdings (SEHK:1060)

Overview: Damai Entertainment Holdings Limited is an investment holding company engaged in content, technology, and IP merchandising and commercialization in Hong Kong and the People's Republic of China, with a market cap of HK$26.89 billion.

Operations: The company's revenue segments include Drama Series Production, which generated CN¥923.11 million.

Estimated Discount To Fair Value: 15.2%

Damai Entertainment Holdings' recent earnings report shows a strong increase in net income to CNY 519.53 million, reflecting robust cash flow generation. The company is trading at a discount to its estimated fair value of HK$1.06, with analysts forecasting significant profit growth of 38% annually, surpassing the Hong Kong market average. Despite this, the stock's return on equity remains modestly low at 7.6%, suggesting potential limitations in profitability efficiency moving forward.

SEHK:1060 Discounted Cash Flow as at Dec 2025

Akeso (SEHK:9926)

Overview: Akeso, Inc. is a biopharmaceutical company focused on the research, development, manufacture, and commercialization of antibody drugs globally with a market cap of HK$110.17 billion.

Operations: The company's revenue primarily comes from its biopharmaceutical products, generating CN¥2.51 billion.

Estimated Discount To Fair Value: 40.3%

Akeso is trading at HK$119.6, significantly below its estimated fair value of HK$200.28, highlighting its potential undervaluation based on cash flows. Analysts forecast Akeso to become profitable within three years, with robust revenue growth expected at 34.8% annually, outpacing the Hong Kong market average. Recent developments include regulatory approval for clinical trials of AK152 for Alzheimer's and advancements in ivonescimab's cancer treatment trials, reinforcing Akeso's innovative pipeline and potential long-term value creation.

SEHK:9926 Discounted Cash Flow as at Dec 2025

Beiqi Foton MotorLtd (SHSE:600166)

Overview: Beiqi Foton Motor Co., Ltd. is involved in the manufacture and sale of commercial vehicles globally, with a market cap of CN¥22.33 billion.

Operations: The company generates revenue from its global operations in the manufacture and sale of commercial vehicles.

Estimated Discount To Fair Value: 36.3%

Beiqi Foton Motor Ltd. trades at CN¥2.82, significantly below its estimated fair value of CN¥4.43, indicating potential undervaluation based on cash flows. Recent earnings show robust growth with net income rising to CNY 1.11 billion from CNY 432 million year-on-year, reflecting strong financial performance despite low forecasted return on equity of 11.4%. The launch of innovative products like GALAXUS and DAYSTAR highlights strategic advancements in green logistics solutions, supporting future revenue growth expectations exceeding the market average.

SHSE:600166 Discounted Cash Flow as at Dec 2025

Seize The Opportunity

Seeking Other Investments?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Akeso might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com